ADVERSE REACTIONS SECTION.

6 ADVERSE REACTIONS. The following clinically significant adverse reactions are discussed in greater detail in other sections of the labeling:Splenic Rupture [see Warnings and Precautions (5.1)] Acute Respiratory Distress Syndrome [see Warnings and Precautions (5.2)] Serious Allergic Reactions [see Warnings and Precautions (5.3)] Allergies to Acrylics [see Warnings and Precautions (5.4)] Use in Patients with Sickle Cell Disorders [see Warnings and Precautions (5.5)] Glomerulonephritis [see Warnings and Precautions (5.6)] Leukocytosis [see Warnings and Precautions (5.7)] Thrombocytopenia [see Warnings and Precautions (5.8)] Capillary Leak Syndrome [see Warnings and Precautions (5.9)] Potential for Tumor Growth Stimulatory Effects on Malignant Cells [see Warnings and Precautions (5.10)] Myelodysplastic syndrome [see Warnings and Precautions (5.11)] Acute myeloid leukemia [see Warnings and Precautions (5.11)] Aortitis [see Warnings and Precautions (5.13)] Splenic Rupture [see Warnings and Precautions (5.1)] Acute Respiratory Distress Syndrome [see Warnings and Precautions (5.2)] Serious Allergic Reactions [see Warnings and Precautions (5.3)] Allergies to Acrylics [see Warnings and Precautions (5.4)] Use in Patients with Sickle Cell Disorders [see Warnings and Precautions (5.5)] Glomerulonephritis [see Warnings and Precautions (5.6)] Leukocytosis [see Warnings and Precautions (5.7)] Thrombocytopenia [see Warnings and Precautions (5.8)] Capillary Leak Syndrome [see Warnings and Precautions (5.9)] Potential for Tumor Growth Stimulatory Effects on Malignant Cells [see Warnings and Precautions (5.10)] Myelodysplastic syndrome [see Warnings and Precautions (5.11)] Acute myeloid leukemia [see Warnings and Precautions (5.11)] Aortitis [see Warnings and Precautions (5.13)] Most common adverse reactions (>= 5% difference in incidence compared to placebo) are bone pain and pain in extremity. (6.1)To report SUSPECTED ADVERSE REACTIONS, contact Amgen Inc. at 1-800-77-AMGEN (1-800-772-6436) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.. 6.1Clinical Trials Experience. Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.Neulasta clinical trials safety data are based upon 932 patients receiving Neulasta in seven randomized clinical trials. The population was 21 to 88 years of age and 92% female. The ethnicity was 75% Caucasian, 18% Hispanic, 5% Black, and 1% Asian. Patients with breast (n 823), lung and thoracic tumors (n 53) and lymphoma (n 56) received Neulasta after nonmyeloablative cytotoxic chemotherapy. Most patients received single 100 mcg/kg (n 259) or single mg (n 546) dose per chemotherapy cycle over cycles.The following adverse reaction data in Table are from randomized, double-blind, placebo-controlled study in patients with metastatic or non-metastatic breast cancer receiving docetaxel 100 mg/m2 every 21 days (Study 3). total of 928 patients were randomized to receive either mg Neulasta (n 467) or placebo (n 461). The patients were 21 to 88 years of age and 99% female. The ethnicity was 66% Caucasian, 31% Hispanic, 2% Black, and 1% Asian, Native American, or other.The most common adverse reactions occurring in >= 5% of patients and with between-group difference of >= 5% higher in the pegfilgrastim arm in placebo-controlled clinical trials are bone pain and pain in extremity.Table 2. Adverse Reactions with >= 5% Higher Incidence in Neulasta Patients Compared to Placebo in Study 3Body System Adverse ReactionPlacebo(N 461)Neulasta mg SC on Day 2(N 467)Musculoskeletal and connective tissue disorders Bone pain26%31% Pain in extremity4%9%. LeukocytosisIn clinical studies, leukocytosis (WBC counts 100 109/L) was observed in less than 1% of 932 patients with non-myeloid malignancies receiving Neulasta. No complications attributable to leukocytosis were reported in clinical studies.. 6.2 Immunogenicity. As with all therapeutic proteins, there is potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors, including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to pegfilgrastim in the studies described below with the incidence of antibodies in other studies or to other products may be misleading.Binding antibodies to pegfilgrastim were detected using BIAcore assay. The approximate limit of detection for this assay is 500 ng/mL. Pre-existing binding antibodies were detected in approximately 6% (51/849) of patients with metastatic breast cancer. Four of 521 pegfilgrastim-treated subjects who were negative at baseline developed binding antibodies to pegfilgrastim following treatment. None of these patients had evidence of neutralizing antibodies detected using cell-based bioassay.. 6.3 Postmarketing Experience. The following adverse reactions have been identified during post approval use of Neulasta. Because these reactions are reported voluntarily from population of uncertain size, it is not always possible to reliably estimate their frequency or establish causal relationship to drug exposure.Splenic rupture and splenomegaly (enlarged spleen) [see Warnings and Precautions (5.1)] Acute respiratory distress syndrome (ARDS) [see Warnings and Precautions (5.2)] Allergic reactions/hypersensitivity, including anaphylaxis, skin rash, urticaria, generalized erythema, and flushing [see Warnings and Precautions (5.3)] Sickle cell crisis [see Warnings and Precautions (5.5)] Glomerulonephritis [see Warnings and Precautions (5.6)] Leukocytosis [see Warnings and Precautions (5.7)] Thrombocytopenia [see Warnings and Precautions (5.8)] Capillary Leak Syndrome [see Warnings and Precautions (5.9)] Injection site reactionsSweets syndrome (acute febrile neutrophilic dermatosis), cutaneous vasculitisApplication site reactions (including events such as application site hemorrhage, application site pain, application site discomfort, application site bruise, and application site erythema) have been reported with the use of the on-body injector for Neulasta.Contact dermatitis and local skin reactions such as rash, pruritus, and urticaria have been reported with the use of the on-body injector for Neulasta, possibly indicating hypersensitivity reaction to the adhesive.Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients with breast and lung cancer receiving chemotherapy and/or radiotherapy [see Warnings and Precautions (5.11)] Aortitis [see Warnings and Precautions (5.13)] Alveolar hemorrhage. Splenic rupture and splenomegaly (enlarged spleen) [see Warnings and Precautions (5.1)] Acute respiratory distress syndrome (ARDS) [see Warnings and Precautions (5.2)] Allergic reactions/hypersensitivity, including anaphylaxis, skin rash, urticaria, generalized erythema, and flushing [see Warnings and Precautions (5.3)] Sickle cell crisis [see Warnings and Precautions (5.5)] Glomerulonephritis [see Warnings and Precautions (5.6)] Leukocytosis [see Warnings and Precautions (5.7)] Thrombocytopenia [see Warnings and Precautions (5.8)] Capillary Leak Syndrome [see Warnings and Precautions (5.9)] Injection site reactions. Sweets syndrome (acute febrile neutrophilic dermatosis), cutaneous vasculitis. Application site reactions (including events such as application site hemorrhage, application site pain, application site discomfort, application site bruise, and application site erythema) have been reported with the use of the on-body injector for Neulasta.. Contact dermatitis and local skin reactions such as rash, pruritus, and urticaria have been reported with the use of the on-body injector for Neulasta, possibly indicating hypersensitivity reaction to the adhesive.. Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients with breast and lung cancer receiving chemotherapy and/or radiotherapy [see Warnings and Precautions (5.11)] Aortitis [see Warnings and Precautions (5.13)] Alveolar hemorrhage.

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION.

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility. No carcinogenicity or mutagenesis studies have been performed with pegfilgrastim.Pegfilgrastim did not affect reproductive performance or fertility in male or female rats at cumulative weekly doses approximately to times higher than the recommended human dose (based on body surface area).

CLINICAL PHARMACOLOGY SECTION.

12 CLINICAL PHARMACOLOGY. 12.1 Mechanism of Action. Pegfilgrastim is colony-stimulating factor that acts on hematopoietic cells by binding to specific cell surface receptors, thereby stimulating proliferation, differentiation, commitment, and end cell functional activation.. 12.2 Pharmacodynamics. Animal data and clinical data in humans suggest correlation between pegfilgrastim exposure and the duration of severe neutropenia as predictor of efficacy. Selection of the dosing regimen of Neulasta is based on reducing the duration of severe neutropenia.. 12.3 Pharmacokinetics. The pharmacokinetics of pegfilgrastim was studied in 379 patients with cancer. The pharmacokinetics of pegfilgrastim was nonlinear, and clearance decreased with increases in dose. Neutrophil receptor binding is an important component of the clearance of pegfilgrastim, and serum clearance is directly related to the number of neutrophils. In addition to numbers of neutrophils, body weight appeared to be factor. Patients with higher body weights experienced higher systemic exposure to pegfilgrastim after receiving dose normalized for body weight. large variability in the pharmacokinetics of pegfilgrastim was observed. The half-life of Neulasta ranged from 15 to 80 hours after subcutaneous injection. In healthy volunteers, the pharmacokinetics of pegfilgrastim were comparable when delivered subcutaneously via manual prefilled syringe versus via the on-body injector (OBI) for Neulasta.. Specific PopulationsNo gender-related differences were observed in the pharmacokinetics of pegfilgrastim, and no differences were observed in the pharmacokinetics of geriatric patients (>= 65 years of age) compared with younger patients (< 65 years of age) [see Use in Specific Populations (8.5)]. Renal ImpairmentIn study of 30 subjects with varying degrees of renal dysfunction, including end stage renal disease, renal dysfunction had no effect on the pharmacokinetics of pegfilgrastim.. Pediatric Patients with Cancer Receiving Myelosuppressive ChemotherapyThe pharmacokinetics and safety of pegfilgrastim were studied in 37 pediatric patients with sarcoma in Study [see Clinical Studies (14.1)]. The mean (+- standard deviation [SD]) systemic exposure (AUC0-inf) of Neulasta after subcutaneous administration at 100 mcg/kg was 47.9 (+- 22.5) mcghr/mL in the youngest age group (0 to years, = 11), 22.0 (+- 13.1) mcghr/mL in the to 11 years age group (n 10), and 29.3 (+- 23.2) mcghr/mL in the 12 to 21 years age group (n 13). The terminal elimination half-lives of the corresponding age groups were 30.1 (+- 38.2) hours, 20.2 (+- 11.3) hours, and 21.2 (+- 16.0) hours, respectively. Patients Acutely Exposed to Myelosuppressive Doses of RadiationThe pharmacokinetics of pegfilgrastim is not available in patients acutely exposed to myelosuppressive doses of radiation. Based on limited pharmacokinetic data in irradiated non-human primates, the area under the concentration-time curve (AUC), reflecting the exposure to pegfilgrastim in non-human primates following 300 mcg/kg dose of Neulasta, appears to be greater than in humans receiving 6 mg dose. Results from population modeling and simulation indicate that two mg doses of Neulasta administered one week apart in adults result in clinically relevant effects on duration of grade and neutropenia. In addition, weight based dosing in pediatric patients weighing less than 45 kg [see Dosage and Administration, Section 2.3, Table 1] provides exposures comparable to those in adults receiving two mg doses one week apart.

CLINICAL STUDIES SECTION.

14 CLINICAL STUDIES. 14.1 Patients with Cancer Receiving Myelosuppressive Chemotherapy. Neulasta was evaluated in three randomized, double-blind, controlled studies. Studies and were active-controlled studies that employed doxorubicin 60 mg/m2 and docetaxel 75 mg/m2 administered every 21 days for up to cycles for the treatment of metastatic breast cancer. Study investigated the utility of fixed dose of Neulasta. Study employed weight-adjusted dose. In the absence of growth factor support, similar chemotherapy regimens have been reported to result in 100% incidence of severe neutropenia (ANC 0.5 109/L) with mean duration of to days and 30% to 40% incidence of febrile neutropenia. Based on the correlation between the duration of severe neutropenia and the incidence of febrile neutropenia found in studies with filgrastim, duration of severe neutropenia was chosen as the primary endpoint in both studies, and the efficacy of Neulasta was demonstrated by establishing comparability to filgrastim-treated patients in the mean days of severe neutropenia.In Study 1, 157 patients were randomized to receive single subcutaneous injection of Neulasta (6 mg) on day of each chemotherapy cycle or daily subcutaneous filgrastim (5 mcg/kg/day) beginning on day of each chemotherapy cycle. In Study 2, 310 patients were randomized to receive single subcutaneous injection of Neulasta (100 mcg/kg) on day or daily subcutaneous filgrastim (5 mcg/kg/day) beginning on day of each chemotherapy cycle.Both studies met the major efficacy outcome measure of demonstrating that the mean days of severe neutropenia of Neulasta-treated patients did not exceed that of filgrastim-treated patients by more than day in cycle of chemotherapy. The mean days of cycle severe neutropenia in Study were 1.8 days in the Neulasta arm compared to 1.6 days in the filgrastim arm [difference in means 0.2 (95% CI 0.2, 0.6)] and in Study were 1.7 days in the Neulasta arm compared to 1.6 days in the filgrastim arm [difference in means 0.1 (95% CI 0.2, 0.4)].A secondary endpoint in both studies was days of severe neutropenia in cycles through with results similar to those for cycle 1.Study was randomized, double-blind, placebo-controlled study that employed docetaxel 100 mg/m2 administered every 21 days for up to cycles for the treatment of metastatic or non-metastatic breast cancer. In this study, 928 patients were randomized to receive single subcutaneous injection of Neulasta (6 mg) or placebo on day of each chemotherapy cycle. Study met the major trial outcome measure of demonstrating that the incidence of febrile neutropenia (defined as temperature >= 38.2C and ANC <= 0.5 109/L) was lower for Neulasta-treated patients as compared to placebo-treated patients (1% versus 17%, respectively, < 0.001). The incidence of hospitalizations (1% versus 14%) and IV anti-infective use (2% versus 10%) for the treatment of febrile neutropenia was also lower in the Neulasta-treated patients compared to the placebo-treated patients.Study was multicenter, randomized, open-label study to evaluate the efficacy, safety, and pharmacokinetics [see Clinical Pharmacology (12.3)] of Neulasta in pediatric and young adult patients with sarcoma. Patients with sarcoma receiving chemotherapy age to 21 years were eligible. Patients were randomized to receive subcutaneous Neulasta as single-dose of 100 mcg/kg (n 37) or subcutaneous filgrastim at dose mcg/kg/day (n 6) following myelosuppressive chemotherapy. Recovery of neutrophil counts was similar in the Neulasta and filgrastim groups. The most common adverse reaction reported was bone pain.. 14.2 Patients with Hematopoietic Subsyndrome of Acute Radiation Syndrome. Efficacy studies of Neulasta could not be conducted in humans with acute radiation syndrome for ethical and feasibility reasons. Approval of this indication was based on efficacy studies conducted in animals and data supporting Neulastas effect on severe neutropenia in patients with cancer receiving myelosuppressive chemotherapy [see Dosage and Administration (2.1)].The recommended dose of Neulasta is two doses, mg each, administered one week apart for humans exposed to myelosuppressive doses of radiation. For pediatric patients weighing less than 45 kg, dosing of Neulasta is weight based and is provided in Table [see Dosage and Administration (2.3)]. This dosing regimen is based on population modeling and simulation analyses. The exposure associated with this dosing regimen is expected to provide sufficient pharmacodynamic activity to treat humans exposed to myelosuppressive doses of radiation [see Clinical Pharmacology (12.3)]. The safety of Neulasta at dose of mg has been assessed on the basis of clinical experience in patients with cancer receiving myelosuppressive chemotherapy.The efficacy of Neulasta for the acute radiation syndrome setting was studied in randomized, placebo-controlled non-human primate model of radiation injury. Rhesus macaques were randomized to either control (n 23) or treated (n 23) cohort. On study day 0, animals (n 6 to per irradiation day) were exposed to total body irradiation (TBI) of 7.50 +- 0.15 Gy delivered at 0.8 +- 0.03 Gy/min, representing dose that would be lethal in 50% of animals by 60 days of follow-up (LD50/60). Animals were administered subcutaneous injections of blinded treatment (control article [5% dextrose in water] or pegfilgrastim [300-319 mcg/kg/day]) on study day and on study day 8. The primary endpoint was survival. Animals received medical management consisting of intravenous fluids, antibiotics, blood transfusions, and other support as required.Pegfilgrastim significantly (at 0.0014 level of significance) increased 60-day survival in irradiated non-human primates: 91% survival (21/23) in the pegfilgrastim group compared to 48% survival (11/23) in the control group.

CLINICAL TRIALS EXPERIENCE SECTION.

6.1Clinical Trials Experience. Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.Neulasta clinical trials safety data are based upon 932 patients receiving Neulasta in seven randomized clinical trials. The population was 21 to 88 years of age and 92% female. The ethnicity was 75% Caucasian, 18% Hispanic, 5% Black, and 1% Asian. Patients with breast (n 823), lung and thoracic tumors (n 53) and lymphoma (n 56) received Neulasta after nonmyeloablative cytotoxic chemotherapy. Most patients received single 100 mcg/kg (n 259) or single mg (n 546) dose per chemotherapy cycle over cycles.The following adverse reaction data in Table are from randomized, double-blind, placebo-controlled study in patients with metastatic or non-metastatic breast cancer receiving docetaxel 100 mg/m2 every 21 days (Study 3). total of 928 patients were randomized to receive either mg Neulasta (n 467) or placebo (n 461). The patients were 21 to 88 years of age and 99% female. The ethnicity was 66% Caucasian, 31% Hispanic, 2% Black, and 1% Asian, Native American, or other.The most common adverse reactions occurring in >= 5% of patients and with between-group difference of >= 5% higher in the pegfilgrastim arm in placebo-controlled clinical trials are bone pain and pain in extremity.Table 2. Adverse Reactions with >= 5% Higher Incidence in Neulasta Patients Compared to Placebo in Study 3Body System Adverse ReactionPlacebo(N 461)Neulasta mg SC on Day 2(N 467)Musculoskeletal and connective tissue disorders Bone pain26%31% Pain in extremity4%9%. LeukocytosisIn clinical studies, leukocytosis (WBC counts 100 109/L) was observed in less than 1% of 932 patients with non-myeloid malignancies receiving Neulasta. No complications attributable to leukocytosis were reported in clinical studies.

CONTRAINDICATIONS SECTION.

4 CONTRAINDICATIONS. Neulasta is contraindicated in patients with history of serious allergic reactions to pegfilgrastim or filgrastim. Reactions have included anaphylaxis [see Warnings and Precautions (5.3)].. Patients with history of serious allergic reactions to human granulocyte colony-stimulating factors such as pegfilgrastim or filgrastim. (4).

DESCRIPTION SECTION.

11 DESCRIPTION. Pegfilgrastim is covalent conjugate of recombinant methionyl human G-CSF (filgrastim) and monomethoxypolyethylene glycol. Filgrastim is water-soluble 175 amino acid protein with molecular weight of approximately 19 kilodaltons (kD). Filgrastim is obtained from the bacterial fermentation of strain of coli transformed with genetically engineered plasmid containing the human G-CSF gene. To produce pegfilgrastim, 20 kD monomethoxypolyethylene glycol molecule is covalently bound to the N-terminal methionyl residue of filgrastim. The average molecular weight of pegfilgrastim is approximately 39 kD.Neulasta is provided in two presentations:Neulasta for manual subcutaneous injection is supplied in 0.6 mL prefilled syringes. The prefilled syringe does not bear graduation marks and is designed to deliver the entire contents of the syringe (6 mg/0.6 mL).On-body injector (OBI) for Neulasta is supplied with prefilled syringe containing 0.64 mL of Neulasta in solution that delivers 0.6 mL of Neulasta in solution when used with the OBI for Neulasta. The syringe does not bear graduation marks and is only to be used with the OBI for Neulasta.The delivered 0.6 mL dose from either the prefilled syringe for manual subcutaneous injection or the OBI for Neulasta contains mg pegfilgrastim (based on protein weight) in sterile, clear, colorless, preservative-free solution (pH 4.0) containing acetate (0.35 mg), polysorbate 20 (0.02 mg), sodium (0.02 mg), and sorbitol (30 mg) in Water for Injection, USP.. Neulasta for manual subcutaneous injection is supplied in 0.6 mL prefilled syringes. The prefilled syringe does not bear graduation marks and is designed to deliver the entire contents of the syringe (6 mg/0.6 mL).. On-body injector (OBI) for Neulasta is supplied with prefilled syringe containing 0.64 mL of Neulasta in solution that delivers 0.6 mL of Neulasta in solution when used with the OBI for Neulasta. The syringe does not bear graduation marks and is only to be used with the OBI for Neulasta.

DOSAGE & ADMINISTRATION SECTION.

2 DOSAGE AND ADMINISTRATION. Patients with cancer receiving myelosuppressive chemotherapy6 mg administered subcutaneously once per chemotherapy cycle. (2.1)Do not administer between 14 days before and 24 hours after administration of cytotoxic chemotherapy. (2.1)Use weight based dosing for pediatric patients weighing less than 45 kg; refer to Table 1. (2.3) Patients acutely exposed to myelosuppressive doses of radiationTwo doses, mg each, administered subcutaneously one week apart. Administer the first dose as soon as possible after suspected or confirmed exposure to myelosuppressive doses of radiation, and second dose one week after. (2.2)Use weight based dosing for pediatric patients weighing less than 45 kg; refer to Table 1. (2.3) Patients with cancer receiving myelosuppressive chemotherapy6 mg administered subcutaneously once per chemotherapy cycle. (2.1)Do not administer between 14 days before and 24 hours after administration of cytotoxic chemotherapy. (2.1)Use weight based dosing for pediatric patients weighing less than 45 kg; refer to Table 1. (2.3) 6 mg administered subcutaneously once per chemotherapy cycle. (2.1). Do not administer between 14 days before and 24 hours after administration of cytotoxic chemotherapy. (2.1). Use weight based dosing for pediatric patients weighing less than 45 kg; refer to Table 1. (2.3). Patients acutely exposed to myelosuppressive doses of radiationTwo doses, mg each, administered subcutaneously one week apart. Administer the first dose as soon as possible after suspected or confirmed exposure to myelosuppressive doses of radiation, and second dose one week after. (2.2)Use weight based dosing for pediatric patients weighing less than 45 kg; refer to Table 1. (2.3) Two doses, mg each, administered subcutaneously one week apart. Administer the first dose as soon as possible after suspected or confirmed exposure to myelosuppressive doses of radiation, and second dose one week after. (2.2). Use weight based dosing for pediatric patients weighing less than 45 kg; refer to Table 1. (2.3). 2.1 Patients with Cancer Receiving Myelosuppressive Chemotherapy. The recommended dosage of Neulasta is single subcutaneous injection of mg administered once per chemotherapy cycle. For dosing in pediatric patients weighing less than 45 kg, refer to Table 1. Do not administer Neulasta between 14 days before and 24 hours after administration of cytotoxic chemotherapy. 2.2 Patients with Hematopoietic Subsyndrome of Acute Radiation Syndrome. The recommended dose of Neulasta is two doses, mg each, administered subcutaneously one week apart. For dosing in pediatric patients weighing less than 45 kg, refer to Table 1. Administer the first dose as soon as possible after suspected or confirmed exposure to radiation levels greater than gray (Gy). Administer the second dose one week after the first dose. Obtain baseline complete blood count (CBC). Do not delay administration of Neulasta if CBC is not readily available. Estimate patients absorbed radiation dose (i.e., level of radiation exposure) based on information from public health authorities, biodosimetry if available, or clinical findings such as time to onset of vomiting or lymphocyte depletion kinetics. 2.3 Administration Neulasta is administered subcutaneously via single-dose prefilled syringe for manual use or for use with the on-body injector (OBI) for Neulasta, which is co-packaged with single-dose prefilled syringe. Use of the OBI for Neulasta is not recommended for patients with Hematopoietic Subsyndrome of Acute Radiation Syndrome. Use of the OBI for Neulasta has not been studied in pediatric patients. Prior to use, remove the carton from the refrigerator and allow the Neulasta prefilled syringe to reach room temperature for minimum of 30 minutes. Discard any prefilled syringe left at room temperature for greater than 48 hours.Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not administer Neulasta if discoloration or particulates are observed.The needle cap on the prefilled syringes contains dry natural rubber (derived from latex); persons with latex allergies should not administer these products.. Pediatric Patients weighing less than 45 kgThe Neulasta prefilled syringe is not designed to allow for direct administration of doses less than 0.6 mL (6 mg). The syringe does not bear graduation marks, which are necessary to accurately measure doses of Neulasta less than 0.6 mL (6 mg) for direct administration to patients. Thus, the direct administration to patients requiring dosing of less than 0.6 mL (6 mg) is not recommended due to the potential for dosing errors. Refer to Table 1.Table 1. Dosing of Neulasta for pediatric patients weighing less than 45 kgBody WeightNeulasta DoseVolume to AdministerLess than 10 kgFor pediatric patients weighing less than 10 kg, administer 0.1 mg/kg (0.01 mL/kg) of Neulasta. See below See below 10 20 kg1.5 mg0.15 mL21 30 kg2.5 mg0.25 mL31 44 kg4 mg0.4 mL. 2.4 Special Healthcare Provider Instructions for the On-body Injector for Neulasta A healthcare provider must fill the on-body injector (OBI) with Neulasta using the prefilled syringe and then apply the OBI for Neulasta to the patients skin (abdomen or back of arm). The back of the arm may only be used if there is caregiver available to monitor the status of the OBI for Neulasta. Approximately 27 hours after the OBI for Neulasta is applied to the patients skin, Neulasta will be delivered over approximately 45 minutes. healthcare provider may initiate administration with the OBI for Neulasta on the same day as the administration of cytotoxic chemotherapy, as long as the OBI for Neulasta delivers Neulasta no less than 24 hours after administration of cytotoxic chemotherapy.The prefilled syringe co-packaged in Neulasta Onpro(R) kit must only be used with the OBI for Neulasta. The prefilled syringe contains additional solution to compensate for liquid loss during delivery through the OBI for Neulasta. If the prefilled syringe co-packaged in Neulasta Onpro kit is used for manual subcutaneous injection, the patient will receive an overdose. If the single-dose prefilled syringe for manual use is used with the OBI for Neulasta, the patient may receive less than the recommended dose.Do not use the OBI for Neulasta to deliver any other drug product except the Neulasta prefilled syringe co-packaged with the OBI for Neulasta.The OBI for Neulasta should be applied to intact, non-irritated skin on the arm or abdomen. missed dose could occur due to an OBI for Neulasta failure or leakage. If the patient misses dose, new dose should be administered by single-dose prefilled syringe for manual use, as soon as possible after detection.Refer to the Healthcare Provider Instructions for Use for the OBI for Neulasta for full administration information.. 2.5 Advice to Give to Patients Regarding Administration via the On-body Injector for Neulasta. Advise patients to avoid activities such as traveling, driving, or operating heavy machinery during hours 26-29 following application of the on-body injector (OBI) for Neulasta (this includes the 45-minute delivery period plus an hour post-delivery). Patients should have caregiver nearby for the first use.Refer the patient to the dose delivery information written on the Patient Instructions for Use. Provide training to patients to ensure they understand when the dose delivery of Neulasta will begin and how to monitor the OBI for Neulasta for completed delivery. Ensure patients understand how to identify signs of malfunction of OBI for Neulasta [see Warnings and Precautions (5.12) and Patient Counseling Information (17)]. Instruct patients using the OBI to notify their healthcare professional immediately in order to determine the need for replacement dose of Neulasta if they suspect that the device may not have performed as intended [see Warnings and Precautions (5.12)].

DOSAGE FORMS & STRENGTHS SECTION.

3 DOSAGE FORMS AND STRENGTHS. Neulasta is clear, colorless, preservative-free solution available as:Injection: mg/0.6 mL in single-dose prefilled syringe for manual use only.Injection: mg/0.6 mL in single-dose prefilled syringe co-packaged with the on-body injector (OBI) for Neulasta (Neulasta Onpro kit).. Injection: mg/0.6 mL in single-dose prefilled syringe for manual use only.. Injection: mg/0.6 mL in single-dose prefilled syringe co-packaged with the on-body injector (OBI) for Neulasta (Neulasta Onpro kit).. Injection: mg/0.6 mL solution in single-dose prefilled syringe for manual use only. (3)Injection: mg/0.6 mL solution in single-dose prefilled syringe co-packaged with the on-body injector for Neulasta. (3). Injection: mg/0.6 mL solution in single-dose prefilled syringe for manual use only. (3). Injection: mg/0.6 mL solution in single-dose prefilled syringe co-packaged with the on-body injector for Neulasta. (3).

GERIATRIC USE SECTION.

8.5 Geriatric Use. Of the 932 patients with cancer who received Neulasta in clinical studies, 139 (15%) were aged 65 and over, and 18 (2%) were aged 75 and over. No overall differences in safety or effectiveness were observed between patients aged 65 and older and younger patients.

HOW SUPPLIED SECTION.

16 HOW SUPPLIED/STORAGE AND HANDLING. Neulasta single-dose prefilled syringe for manual use Neulasta injection is clear, colorless solution supplied in prefilled single-dose syringe for manual use containing mg pegfilgrastim, supplied with 27-gauge, 1/2-inch needle with an UltraSafe(R) Needle Guard.The needle cap of the prefilled syringe contains dry natural rubber (a derivative of latex).Neulasta is provided in dispensing pack containing one sterile mg/0.6 mL prefilled syringe (NDC 55513-190-01).Neulasta prefilled syringe does not bear graduation marks and is intended only to deliver the entire contents of the syringe (6 mg/0.6 mL) for direct administration. Use of the prefilled syringe is not recommended for direct administration for pediatric patients weighing less than 45 kg who require doses that are less than the full contents of the syringe.. Store refrigerated between 36F to 46F (2C to 8C) in the carton to protect from light. Do not shake. Discard syringes stored at room temperature for more than 48 hours. Avoid freezing; if frozen, thaw in the refrigerator before administration. Discard syringe if frozen more than once.. Neulasta Onpro(R) kitNeulasta Onpro kit is provided in carton containing one sterile prefilled syringe and one sterile on-body injector (OBI) for Neulasta (NDC 55513-192-01).The Neulasta injection single-dose prefilled syringe contains 0.64 mL of clear, colorless solution that delivers mg/0.6 mL of pegfilgrastim when used with the OBI for Neulasta. The prefilled syringe is supplied with 27-gauge, 1/2-inch needle. The syringe does not bear graduation marks and is only to be used with the OBI for Neulasta.The needle cap of the prefilled syringe contains dry natural rubber (a derivative of latex).. Store Neulasta Onpro kit in the refrigerator at 36F to 46F (2C to 8C) until 30 minutes prior to use. Because the OBI for Neulasta is at room temperature during the period of use, Neulasta Onpro kit should not be held at room temperature longer than 12 hours prior to use. Discard Neulasta Onpro kit if stored at room temperature for more than 12 hours. Do not use the OBI for Neulasta if its packaging has been previously opened.

IMMUNOGENICITY.

6.2 Immunogenicity. As with all therapeutic proteins, there is potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors, including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to pegfilgrastim in the studies described below with the incidence of antibodies in other studies or to other products may be misleading.Binding antibodies to pegfilgrastim were detected using BIAcore assay. The approximate limit of detection for this assay is 500 ng/mL. Pre-existing binding antibodies were detected in approximately 6% (51/849) of patients with metastatic breast cancer. Four of 521 pegfilgrastim-treated subjects who were negative at baseline developed binding antibodies to pegfilgrastim following treatment. None of these patients had evidence of neutralizing antibodies detected using cell-based bioassay.

INDICATIONS & USAGE SECTION.

1 INDICATIONS AND USAGE. Neulasta is leukocyte growth factor indicated to Decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia. (1.1) Increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome). (1.2)Limitations of UseNeulasta is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.. Decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia. (1.1). Increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome). (1.2). 1.1 Patients with Cancer Receiving Myelosuppressive Chemotherapy. Neulasta is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia [see Clinical Studies (14.1)].. Limitations of UseNeulasta is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.. 1.2 Patients with Hematopoietic Subsyndrome of Acute Radiation Syndrome. Neulasta is indicated to increase survival in patients acutely exposed to myelosuppressive doses of radiation [see Dosage and Administration (2.2) and Clinical Studies (14.2)].

INFORMATION FOR PATIENTS SECTION.

17 PATIENT COUNSELING INFORMATION. Advise the patient to read the FDA-approved patient labeling (Patient Information and Instructions for Use).Advise patients of the following risks and potential risks with Neulasta:Splenic rupture and splenomegalyAcute Respiratory Distress SyndromeSerious allergic reactionsSickle cell crisisGlomerulonephritisIncreased risk of Myelodysplastic Syndrome and/or Acute Myeloid Leukemia in patients with breast and lung cancer who receive Neulasta in conjunction with chemotherapy and/or radiation therapyCapillary Leak SyndromeAortitisAdvise patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome) that efficacy studies of Neulasta for this indication could not be conducted in humans for ethical and feasibility reasons and that, therefore, approval of this use was based on efficacy studies conducted in animals [see Clinical Studies (14.2)].Instruct patients who self-administer Neulasta using the single-dose prefilled syringe of the:Importance of following the Instructions for Use.Dangers of reusing syringes.Importance of following local requirements for proper disposal of used syringes.Advise patients on the use of the on-body injector (OBI) for Neulasta:Review the Patient Information and Patient Instructions for Use with the patient and provide the instructions to the patient.Refer the patient to the dose delivery information written on the Patient Instructions for Use. Tell the patient when their dose delivery of Neulasta will begin and when their dose delivery should be completed. Advise the patient that serious allergic reactions can happen with Neulasta. Patients should have caregiver nearby for the first use. Patients should plan to be in place where they can appropriately monitor the OBI for Neulasta during the approximately 45 minute Neulasta delivery and for an hour after the delivery. Advise the patient to avoid traveling, driving, or operating heavy machinery during hours 26-29 following application of the OBI for Neulasta. If the OBI for Neulasta is placed on the back of the arm, remind the patient that caregiver must be available to monitor the OBI for Neulasta. If patient calls the healthcare provider regarding any OBI for Neulasta problems, the healthcare provider is advised to call Amgen at 1-800-772-6436.Advise the patient:to call their healthcare provider immediately if the status light on the OBI for Neulasta is flashing red (see the Patient Instructions for Use).to inform their healthcare provider if the adhesive on the OBI for Neulasta becomes saturated with fluid, or there is dripping, as this may be evidence of significant product leakage, resulting in inadequate or missed dose (see the Patient Instructions for Use).to keep the OBI for Neulasta dry for approximately the last hours prior to the dose delivery start to better enable potential leak detection.that the OBI for Neulasta should only be exposed to temperatures between 41F and 104F (5C-40C).to keep the OBI for Neulasta at least inches away from electrical equipment such as cell phones, cordless telephones, microwaves, and other common appliances. Failure to keep the OBI for Neulasta at least this recommended distance may interfere with operation and can lead to missed or incomplete dose of Neulasta.that if the needle is exposed after OBI for Neulasta removal, place the used OBI for Neulasta in sharps disposal container to avoid accidental needle stick and call their healthcare provider immediately.to remove the OBI for Neulasta after the green light shines continuously and to place the used OBI for Neulasta in sharps disposal container (see the Patient Instructions for Use). Advise the patient: do not reapply the OBI for Neulasta if the OBI for Neulasta comes off before full dose is delivered and instead call their healthcare provider immediately, as they may need replacement dose. avoid bumping the OBI for Neulasta or knocking the OBI for Neulasta off the body. do not use other materials to hold the on-body injector in place that could cover audio/visual indicators or compress the on-body injector against the patients skin, as this could dislodge the cannula and lead to missed dose or incomplete dose of Neulasta.do not expose the OBI for Neulasta to medical imaging studies (e.g., X-ray scan, MRI, CT scan and ultrasound), radiation treatment, and oxygen rich environments such as hyperbaric chambers to avoid OBI for Neulasta damage and patient injury. Advise the patient to avoid:airport X-ray scans and request manual pat down instead; remind patients who elect to request manual pat down to exercise care to avoid having the OBI for Neulasta dislodged during the pat down process.sleeping on the OBI for Neulasta or applying pressure on the OBI for Neulasta as this may affect OBI for Neulasta performance.getting body lotions, creams, oils, and cleaning agents near the OBI for Neulasta as these products may loosen the adhesive.use of lotions, creams, or oils on their arms and abdomen prior to their next scheduled OBI for Neulasta dose (to help with device adherence to the skin).using bath tubs, hot tubs, whirlpools, or saunas and avoid exposing the OBI for Neulasta to direct sunlight as these may affect the drug.peeling off or disturbing the OBI for Neulasta adhesive before delivery of full dose is complete. Splenic rupture and splenomegaly. Acute Respiratory Distress Syndrome. Serious allergic reactions. Sickle cell crisis. Glomerulonephritis. Increased risk of Myelodysplastic Syndrome and/or Acute Myeloid Leukemia in patients with breast and lung cancer who receive Neulasta in conjunction with chemotherapy and/or radiation therapy. Capillary Leak Syndrome. Aortitis. Importance of following the Instructions for Use.. Dangers of reusing syringes.. Importance of following local requirements for proper disposal of used syringes.. Review the Patient Information and Patient Instructions for Use with the patient and provide the instructions to the patient.. Refer the patient to the dose delivery information written on the Patient Instructions for Use. Tell the patient when their dose delivery of Neulasta will begin and when their dose delivery should be completed. Advise the patient that serious allergic reactions can happen with Neulasta. Patients should have caregiver nearby for the first use. Patients should plan to be in place where they can appropriately monitor the OBI for Neulasta during the approximately 45 minute Neulasta delivery and for an hour after the delivery. Advise the patient to avoid traveling, driving, or operating heavy machinery during hours 26-29 following application of the OBI for Neulasta. If the OBI for Neulasta is placed on the back of the arm, remind the patient that caregiver must be available to monitor the OBI for Neulasta. If patient calls the healthcare provider regarding any OBI for Neulasta problems, the healthcare provider is advised to call Amgen at 1-800-772-6436.. Advise the patient:to call their healthcare provider immediately if the status light on the OBI for Neulasta is flashing red (see the Patient Instructions for Use).to inform their healthcare provider if the adhesive on the OBI for Neulasta becomes saturated with fluid, or there is dripping, as this may be evidence of significant product leakage, resulting in inadequate or missed dose (see the Patient Instructions for Use).to keep the OBI for Neulasta dry for approximately the last hours prior to the dose delivery start to better enable potential leak detection.that the OBI for Neulasta should only be exposed to temperatures between 41F and 104F (5C-40C).to keep the OBI for Neulasta at least inches away from electrical equipment such as cell phones, cordless telephones, microwaves, and other common appliances. Failure to keep the OBI for Neulasta at least this recommended distance may interfere with operation and can lead to missed or incomplete dose of Neulasta.that if the needle is exposed after OBI for Neulasta removal, place the used OBI for Neulasta in sharps disposal container to avoid accidental needle stick and call their healthcare provider immediately.to remove the OBI for Neulasta after the green light shines continuously and to place the used OBI for Neulasta in sharps disposal container (see the Patient Instructions for Use). to call their healthcare provider immediately if the status light on the OBI for Neulasta is flashing red (see the Patient Instructions for Use).. to inform their healthcare provider if the adhesive on the OBI for Neulasta becomes saturated with fluid, or there is dripping, as this may be evidence of significant product leakage, resulting in inadequate or missed dose (see the Patient Instructions for Use).. to keep the OBI for Neulasta dry for approximately the last hours prior to the dose delivery start to better enable potential leak detection.. that the OBI for Neulasta should only be exposed to temperatures between 41F and 104F (5C-40C).. to keep the OBI for Neulasta at least inches away from electrical equipment such as cell phones, cordless telephones, microwaves, and other common appliances. Failure to keep the OBI for Neulasta at least this recommended distance may interfere with operation and can lead to missed or incomplete dose of Neulasta.. that if the needle is exposed after OBI for Neulasta removal, place the used OBI for Neulasta in sharps disposal container to avoid accidental needle stick and call their healthcare provider immediately.. to remove the OBI for Neulasta after the green light shines continuously and to place the used OBI for Neulasta in sharps disposal container (see the Patient Instructions for Use).. Advise the patient: do not reapply the OBI for Neulasta if the OBI for Neulasta comes off before full dose is delivered and instead call their healthcare provider immediately, as they may need replacement dose. avoid bumping the OBI for Neulasta or knocking the OBI for Neulasta off the body. do not use other materials to hold the on-body injector in place that could cover audio/visual indicators or compress the on-body injector against the patients skin, as this could dislodge the cannula and lead to missed dose or incomplete dose of Neulasta.do not expose the OBI for Neulasta to medical imaging studies (e.g., X-ray scan, MRI, CT scan and ultrasound), radiation treatment, and oxygen rich environments such as hyperbaric chambers to avoid OBI for Neulasta damage and patient injury. do not reapply the OBI for Neulasta if the OBI for Neulasta comes off before full dose is delivered and instead call their healthcare provider immediately, as they may need replacement dose.. avoid bumping the OBI for Neulasta or knocking the OBI for Neulasta off the body.. do not use other materials to hold the on-body injector in place that could cover audio/visual indicators or compress the on-body injector against the patients skin, as this could dislodge the cannula and lead to missed dose or incomplete dose of Neulasta.. do not expose the OBI for Neulasta to medical imaging studies (e.g., X-ray scan, MRI, CT scan and ultrasound), radiation treatment, and oxygen rich environments such as hyperbaric chambers to avoid OBI for Neulasta damage and patient injury.. Advise the patient to avoid:airport X-ray scans and request manual pat down instead; remind patients who elect to request manual pat down to exercise care to avoid having the OBI for Neulasta dislodged during the pat down process.sleeping on the OBI for Neulasta or applying pressure on the OBI for Neulasta as this may affect OBI for Neulasta performance.getting body lotions, creams, oils, and cleaning agents near the OBI for Neulasta as these products may loosen the adhesive.use of lotions, creams, or oils on their arms and abdomen prior to their next scheduled OBI for Neulasta dose (to help with device adherence to the skin).using bath tubs, hot tubs, whirlpools, or saunas and avoid exposing the OBI for Neulasta to direct sunlight as these may affect the drug.peeling off or disturbing the OBI for Neulasta adhesive before delivery of full dose is complete. airport X-ray scans and request manual pat down instead; remind patients who elect to request manual pat down to exercise care to avoid having the OBI for Neulasta dislodged during the pat down process.. sleeping on the OBI for Neulasta or applying pressure on the OBI for Neulasta as this may affect OBI for Neulasta performance.. getting body lotions, creams, oils, and cleaning agents near the OBI for Neulasta as these products may loosen the adhesive.. use of lotions, creams, or oils on their arms and abdomen prior to their next scheduled OBI for Neulasta dose (to help with device adherence to the skin).. using bath tubs, hot tubs, whirlpools, or saunas and avoid exposing the OBI for Neulasta to direct sunlight as these may affect the drug.. peeling off or disturbing the OBI for Neulasta adhesive before delivery of full dose is complete.

INSTRUCTIONS FOR USE SECTION.

Neulasta(R) (pegfilgrastim) Onpro(R) kit Healthcare Provider INSTRUCTIONS FOR USE. Guide to Parts Neulasta Prefilled SyringeOn-body Injector for NeulastaImportantREAD THE FOLLOWING INSTRUCTIONS BEFORE USING NEULASTA ONPRO KITPrescribing InformationSee Prescribing Information for information on Neulasta.The on-body injector is for adult patients only. The on-body injector is not recommended for patients with Hematopoietic Subsyndrome of Acute Radiation Syndrome.Neulasta prefilled syringe gray needle cap contains dry natural rubber, which is derived from latex.For patients who have had severe skin reactions to acrylic adhesives, consider the benefit:risk profile before administering pegfilgrastim via the on-body injector for Neulasta.Application InformationThe on-body injector should be applied to intact, non-irritated skin on the abdomen or back of the arm. The back of the arm may only be used if there is caregiver available to monitor the status of the on-body injector.The on-body injector has self-adhesive backing to attach it to the skin, do not use additional materials to hold it in place as this could dislodge the cannula and lead to missed or incomplete dose of Neulasta.Environmental InformationDo not expose the on-body injector for Neulasta to the following environments as the on-body injector may be damaged and the patient could be injured:Diagnostic imaging (e.g., CT Scan, MRI, Ultrasound, X-ray)Radiation treatmentOxygen rich environments such as hyperbaric chambers CautionsDo not use Neulasta Onpro kit to deliver any other drug productDo not use the on-body injector if its packaging has been previously opened, or the expiration date on the carton or any components has passed.Do not use if the name Neulasta does not appear on Neulasta Onpro kit carton.Do not modify the on-body injector.Do not attempt to reapply the on-body injector.Do not use if either the on-body injector or prefilled syringe is dropped. Start again with new kitStorage InformationStore the kit in the refrigerator at 36F to 46F (2C to 8C) until ready for use. If the kit is stored at room temperature for more than 12 hours, do not use. Start again with new kit.Keep the prefilled syringe in the kit carton until use to protect from light.Do not freeze the kit.Do not separate the components of Neulasta Onpro kit until ready for use.For all questions, or if patient calls you regarding any injector problems, call Amgen at 1-800-772-6436.Step 1: PrepareAPlace the syringe tray and the on-body injector tray on clean, well-lit work surface.Allow the syringe and on-body injector to come naturally to room temperature for 30 minutes prior to activating. Do not warm the kit components using heat source.BChoose the patients injection site.Ask the patient about their ability to monitor and remove the on-body injector.Use the left or right side of the abdomen, except for two-inch area right around navel.Use the back of upper arm only if there is caregiver available to monitor the status of the on-body injector.Apply the on-body injector to intact, non-irritated skin.Do not apply the on-body injector on surgical sites or areas with scar tissue, moles, or excessive hair. In case of excessive hair, carefully trim hair to get the on-body injector close to the skin.Do not apply the on-body injector on areas where belts, waistbands, or tight clothing may rub against, disturb, or dislodge the on-body injector.Do not apply the on-body injector on areas where the on-body injector will be affected by folds in the skin.CClean an area on the injection site larger than the on-body injector adhesive backing.Thoroughly clean the site with alcohol to enhance on-body adherence to the skin. Only use alcohol to clean the skin. Make sure the skin is oil-free prior to applying the on-body injector. Allow the skin to completely dry before attaching the on-body injector. Do not touch this area again before attaching the on-body injector. Remove Neulasta prefilled syringe from tray.DFor safety reasons:Do not grasp the gray needle cap.Do not grasp the plunger rod.EInspect Neulasta prefilled syringe. Neulasta liquid should always be clear and colorless.Do not use if the liquid contains particulate matter or discoloration is observed prior to administration.Do not use the prefilled syringe if the expiration date has passed. Do not use if any part appears cracked or broken.Do not use if the gray needle cap is missing or not securely attached.Do not remove the gray needle cap until ready to fill the on-body injector.Do not shake the prefilled syringe.In all the above cases, start again with new kit.Step 2: FillARemove air bubbles in prefilled syringe.Injecting air bubbles could interfere with proper operation of the on-body injector.Remove the gray needle cap.Gently tap the syringe with your finger until air bubbles rise to the top.Slowly push air out of the syringe, taking care to not expel medicine.A small droplet at the tip of the needle during air purging is normal.Do not recap the syringe. BCenter the needle directly over the medicine port and insert all the way into the port, avoiding sides.Insert needle into medicine port at 90 degree angle only.Do not remove the blue needle cover before filling the on-body injector.Do not insert the needle more than once.Do not bend the needle. Avoid spilling the medicine.CPush the plunger rod to empty entire syringe contents into the on-body injector. During filling, you will hear beeping.The status light will flash amber.You now have full minutes to apply the on-body injector to your patient.Discard used syringe in sharps container.DCheck to see if the on-body injector is full and the amber light is flashing. You should see black line next to FULL on the fill indicator.If this is not the case, do not use. Start again with new Neulasta Onpro kit.EFirmly lift and remove the blue needle cover away from the on-body injector.Step 3: ApplyAPeel away both pull tabs to show the adhesive. Never touch hands or gloves to the adhesive.Make sure skin is dry prior to applying the on-body injector.Do not pull off the adhesive pad or fold it.Do not touch or contaminate the automatic needle area.Do not use if the needle or cannula is extended past the adhesive or is extended before the on-body injector is placed on the patient.Do not place adhesive on skin that is damp.BBefore the cannula inserts, securely apply the on-body injector so it is visible and can be monitored by the patient or caregiver.You now have time to carefully apply the on-body injector without folding or wrinkling the adhesive.Do not touch the adhesive.Grasp the on-body injectors plastic case with your fingertips and only by sides, keeping fingers off of the adhesive.Do not let the adhesive bend or curl while applying the on-body injector to skin.Important: Once on the skin, press firmly on the on-body injector to ensure proper adhesion to the patients skin. Press around the entire adhesive so it lies down without folds or wrinkles.Hold the top of the on-body injector and run finger around the adhesive to create secure attachment.If additional adhesion is deemed appropriate, an adhesive extender that fits around the on-body injector can be obtained by calling 1-844-MYNEULASTA (1-844-696-3852).Do not use other materials to secure the on-body injector to the patient that could cover audio/visual indicators or compress the on-body injector against the patients skin.Back of upper arm (triceps)Vertical with the light facing down toward the elbowAbdomenHorizontal with the light facing up and visible to the patientDo not worry if the on-body injector is quiet. When minutes are up, the on-body injector will beep telling you the cannula is about to insert.Step 4: FinishAWait for the status light to turn green. This means the cannula has been inserted.Do not remove the on-body injector during cannula insertion to avoid needle stick injury to you or to the patient. Check the quality of adhesion before sending the patient home.If the adhesive is wrinkled in front of the cannula window or has folds anywhere that prevent the on-body injector from securely adhering, remove the on-body injector. Start again with new kit and call Amgen at 1-800-772-6436.BProvide the Patient IFU Booklet for the patient to take home. Fill in the Dose Delivery information on the booklet, and review the following instructions with your patient:The on-body injector will always flash slow green light to let them know it is working properly.The patient should keep the on-body injector dry for at least hours after it was placed on their skin.After approximately 27 hours, the dose delivery will begin. Dose delivery will take about 45 minutes, during this time, the on-body injector will flash fast green light.When dose delivery is complete, the on-body injector will sound long beep, and the status light will turn SOLID GREEN.Do not remove the on-body injector until the status light is SOLID GREEN.If the red error light is flashing, or the adhesive is noticeably wet (saturated), or the on-body injector is dislodged, the patient should contact their healthcare provider immediately as they may need replacement dose.AttentionWhat to do if you hear beeping or when you look at status light and it is flashing red.If at any time the on-body injector beeps continuously for minutes, and the status light is flashing red, take the on-body injector off of the patient. Do not apply or leave the on-body injector on the patient if red error light is on.In all cases, do not use. Start over with new Neulasta Onpro kit, and call Amgen at 1-800-772-6436.What to do if your patient reports the status light is flashing red.If the patient reports the status light is flashing red, they may not have received the full dose. Schedule follow-up appointment with your patient.What to do if your patient reports the adhesive is saturated with fluid or the on-body injector is dripping.If the patient reports an on-body injector leak, they may not have received the full dose. Schedule follow-up appointment with your patient.In all cases report the incident to Amgen at 1-800-772-6436.Neulasta(R) (pegfilgrastim)Manufactured by:Amgen Inc.One Amgen Center DriveThousand Oaks, California 91320-1799US License No. 1080Patent: http://pat.amgen.com/onpro/(C) 2002 to 2021 Amgen Inc. All rights reserved.http://www.neulasta.com/1-844-MYNEULASTA (1-844-696-3852) Issued: 03/2021V12Before You BeginThe following is an overview of on-body injector preparation steps. Read this section firstTo prepare and apply the on-body injector, you will use pre-filled syringe to fill and activate it. As part of this process, the on-body injector uses lights and sounds as signals to help guide you through the preparation and application process. As you fill the on-body injector, the status light flashes amber and the on-body injector beeps times.When the status light flashes amber and the on-body injector beeps, this means it has been properly filled and activated.After the on-body injector activates, you will have full minutes to remove the blue needle guard and adhesive backing, and then apply the on-body injector to your patient. The on-body injector will beep several times prior to inserting the cannula. Make sure you have the on-body injector properly secured to your patient before the cannula inserts. When the status light flashes green, this means the on-body injector has successfully inserted the cannula.For all questions, or if patient calls you regarding any on-body injector problems, call Amgen at 1-800-772-6436.<- Turn over to continue with the Instructions for Use SymbolMeaningDo not reuse this on-body injector. Single-use onlyRefer to Instructions for UseDo not use if packaging is damagedTemperature limitationHumidity limitationExpiration date (use by date)Reference/model numberLot numberType BF medical device (protection from electrical shock)Sterilized by ethylene oxideWaterproof up to feet for hourPrescription use onlyMR UnsafeOn-body injector for Neulasta(R) (pegfilgrastim)Neulasta(R) (pegfilgrastim) prefilled syringePressure LimitationDo not expose the on-body injector for Neulasta to the following environments as the on-body injector may be damaged and the patient could be injured:Diagnostic imaging (e.g., CT Scan, MRI, Ultrasound, X-ray)Radiation treatmentOxygen rich environments such as hyperbaric chambersElectromagnetic CompatibilityThe information contained in this section (such as separation distances) is, in general, specifically written in regard to the on-body injector for Neulasta. The numbers provided will not guarantee faultless operation but should provide reasonable assurance of such. This information may not be applicable to other medical electrical equipment; older equipment may be particularly susceptible to interference.General Notes:Medical electrical equipment requires special precautions regarding electromagnetic compatibility (EMC), and needs to be installed and put into service according to the EMC information provided in this document.Portable and mobile RF communications equipment can affect medical electrical equipment.Cables and accessories not specified within the instructions for use are not authorized. Using cables and/or accessories may adversely impact safety, performance, and electromagnetic compatibility (increased emission and decreased immunity).Care should be taken if the on-body injector for Neulasta is used adjacent to other electrical equipment; if adjacent use is inevitable, the on-body injector for Neulasta should be observed to verify normal operation in this setting.Electromagnetic EmissionsThe on-body injector for Neulasta is intended for use in the electromagnetic environment specified below. The user of the on-body injector for Neulasta should ensure that it is used in such an environment.EmissionsCompliance according toElectromagnetic environmentRF Emissions (CISPR 11)Group 1The on-body injector for Neulasta uses RF energy only for its internal function. Therefore, its RF emissions are very low and are not likely to cause any interference in nearby equipment.CISPR BEmissions ClassificationClass BElectromagnetic ImmunityThe on-body injector for Neulasta is intended for use in the electromagnetic environment specified below. The user of this equipment should ensure that it is used in such an environment.Immunity TestIEC 60601 Test LevelCompliance LevelElectromagnetic Environment-GuidanceESDIEC 61000-4-2+-8 kV Contact+-15 kV Air+-8 kV Contact+-15 kV AirFloors should be wood, concrete or ceramic tile. If floors are synthetic, the r/h should be at least 30%.Power Frequency50/60 HzMagnetic Field IEC61000-4-830 A/m30 A/mPower frequency magnetic fields should be that of typical commercial or hospital environment.Radiated RF Fields61000-4-33 V/m80 MHz to 2.7 GHz(E1)=3 V/mPortable and mobile communications equipment should be separated from the on-body injector for Neulasta by no less than the distances calculated/listed below:D=(3.5/V1)(P)150 kHz to 80 MHzD=(3.5/E1)(P)80 to 800 MHzD=(7/E1)(P)800 MHz to 2.5 GHzWhere is the max power in watts and is the recommended separation distance in meters. Field strengths from fixed transmitters, as determined by an electromagnetic site survey, should be less than the compliance levels (V1 and E1). Interference may occur in the vicinity of equipment containing transmitter.Test specifications for ENCLOSURE PORT IMMUNITY to RF wireless communications equipmentThe on-body injector for Neulasta is intended for use in the radio frequency environment specified below. The user of this equipment should ensure that it is used in such an environment.Test FrequencyBandFor some services, only the uplink frequencies are included. Service ModulationThe carrier shall be modulated using 50% duty cycle square wave signal. Maximum PowerDistanceImmunity Test Level(MHz)(MHz)(W)(m)(V/m)NOTE If necessary to achieve the IMMUNITY TEST LEVEL, the distance between the transmitting antenna and the ME EQUIPMENT OF ME SYSTEM may be reduced to m. The m test distance is permitted by IEC 61000-4-3.385380-390TETRA 400Pulse modulation 18 Hz1.80.327450430-470GMRS 460, FRS 460FM As an alternative to FM modulation, 50% pulse modulation at 18 Hz may be used because while it does not represent actual modulation, it would be worst case. +- kHz deviation1 kHz sine20.328710704-787LTE Band 13, 17Pulse modulation 217 Hz0.20.39745780810800-960GSM 800/900,TETRA 800,iDEN 820,CDMA 850,LTE Band 5Pulse modulation 18 Hz20.32887093017201700-1990GSM 1800;CDMA 1900;GSM 1900;DECT;LTE Band 1, 3, 4, 25; UMTSPulse modulation 217 Hz20.3281845197024502400-2570Bluetooth,WLAN,802.11 b/g/n,RFID 2450,LTE Band 7Pulse modulation 217 Hz20.32852405100-5800WLAN 802.11 a/nPulse modulation 217 Hz0.20.3955005785Recommended separation distances between portable and mobile RF communications equipment and the on-body injector for Neulasta You can help prevent electromagnetic interference by maintaining minimum distance between portable and mobile RF communications equipment (transmitters) and the on-body injector for Neulasta, as recommended below, according to the maximum power of the communication equipment.Rated maximum output power of transmitter, in wattsSeparation distance according to frequency of transmitter, in meters150 kHz to 80 MHz80 MHz to 800 MHz800 MHz to 2.5 GHzD=(3.5/V1)(P)D=(3.5/E1)(P)D=(7/E1)(P)0.010.116670.116670.233330.10.368940.368940.7378511.16671.16672.3333103.68943.68947.378510011.66711.66723.333. See Prescribing Information for information on Neulasta.. The on-body injector is for adult patients only. The on-body injector is not recommended for patients with Hematopoietic Subsyndrome of Acute Radiation Syndrome.. Neulasta prefilled syringe gray needle cap contains dry natural rubber, which is derived from latex.. For patients who have had severe skin reactions to acrylic adhesives, consider the benefit:risk profile before administering pegfilgrastim via the on-body injector for Neulasta.. The on-body injector should be applied to intact, non-irritated skin on the abdomen or back of the arm. The back of the arm may only be used if there is caregiver available to monitor the status of the on-body injector.. The on-body injector has self-adhesive backing to attach it to the skin, do not use additional materials to hold it in place as this could dislodge the cannula and lead to missed or incomplete dose of Neulasta.. Do not expose the on-body injector for Neulasta to the following environments as the on-body injector may be damaged and the patient could be injured:Diagnostic imaging (e.g., CT Scan, MRI, Ultrasound, X-ray)Radiation treatmentOxygen rich environments such as hyperbaric chambers Diagnostic imaging (e.g., CT Scan, MRI, Ultrasound, X-ray). Radiation treatment. Oxygen rich environments such as hyperbaric chambers. Do not use Neulasta Onpro kit to deliver any other drug product. Do not use the on-body injector if its packaging has been previously opened, or the expiration date on the carton or any components has passed.. Do not use if the name Neulasta does not appear on Neulasta Onpro kit carton.. Do not modify the on-body injector.. Do not attempt to reapply the on-body injector.. Do not use if either the on-body injector or prefilled syringe is dropped. Start again with new kit. Store the kit in the refrigerator at 36F to 46F (2C to 8C) until ready for use. If the kit is stored at room temperature for more than 12 hours, do not use. Start again with new kit.. Keep the prefilled syringe in the kit carton until use to protect from light.. Do not freeze the kit.. Do not separate the components of Neulasta Onpro kit until ready for use.. Use the left or right side of the abdomen, except for two-inch area right around navel.. Use the back of upper arm only if there is caregiver available to monitor the status of the on-body injector.. Apply the on-body injector to intact, non-irritated skin.. Do not apply the on-body injector on surgical sites or areas with scar tissue, moles, or excessive hair. In case of excessive hair, carefully trim hair to get the on-body injector close to the skin.. Do not apply the on-body injector on areas where belts, waistbands, or tight clothing may rub against, disturb, or dislodge the on-body injector.. Do not apply the on-body injector on areas where the on-body injector will be affected by folds in the skin.. Only use alcohol to clean the skin. Make sure the skin is oil-free prior to applying the on-body injector. Allow the skin to completely dry before attaching the on-body injector. Do not touch this area again before attaching the on-body injector.. Do not grasp the gray needle cap.. Do not grasp the plunger rod.. Do not use if the liquid contains particulate matter or discoloration is observed prior to administration.. Do not use the prefilled syringe if the expiration date has passed. Do not use if any part appears cracked or broken.. Do not use if the gray needle cap is missing or not securely attached.. Do not remove the gray needle cap until ready to fill the on-body injector.. Do not shake the prefilled syringe.. Remove the gray needle cap.. Gently tap the syringe with your finger until air bubbles rise to the top.. Slowly push air out of the syringe, taking care to not expel medicine.. small droplet at the tip of the needle during air purging is normal.. Do not recap the syringe. Do not remove the blue needle cover before filling the on-body injector.. Do not insert the needle more than once.. Do not bend the needle. Avoid spilling the medicine.. During filling, you will hear beeping.. The status light will flash amber.. You now have full minutes to apply the on-body injector to your patient.. Do not pull off the adhesive pad or fold it.. Do not touch or contaminate the automatic needle area.. Do not use if the needle or cannula is extended past the adhesive or is extended before the on-body injector is placed on the patient.. Do not place adhesive on skin that is damp.. Do not touch the adhesive.. Grasp the on-body injectors plastic case with your fingertips and only by sides, keeping fingers off of the adhesive.. Do not let the adhesive bend or curl while applying the on-body injector to skin.. Important: Once on the skin, press firmly on the on-body injector to ensure proper adhesion to the patients skin. Press around the entire adhesive so it lies down without folds or wrinkles.. Hold the top of the on-body injector and run finger around the adhesive to create secure attachment.. If additional adhesion is deemed appropriate, an adhesive extender that fits around the on-body injector can be obtained by calling 1-844-MYNEULASTA (1-844-696-3852).. Do not use other materials to secure the on-body injector to the patient that could cover audio/visual indicators or compress the on-body injector against the patients skin.. The on-body injector will always flash slow green light to let them know it is working properly.. The patient should keep the on-body injector dry for at least hours after it was placed on their skin.. After approximately 27 hours, the dose delivery will begin. Dose delivery will take about 45 minutes, during this time, the on-body injector will flash fast green light.. When dose delivery is complete, the on-body injector will sound long beep, and the status light will turn SOLID GREEN.. Do not remove the on-body injector until the status light is SOLID GREEN.. If the red error light is flashing, or the adhesive is noticeably wet (saturated), or the on-body injector is dislodged, the patient should contact their healthcare provider immediately as they may need replacement dose.. Do not apply or leave the on-body injector on the patient if red error light is on.. The on-body injector will beep several times prior to inserting the cannula. Make sure you have the on-body injector properly secured to your patient before the cannula inserts. Diagnostic imaging (e.g., CT Scan, MRI, Ultrasound, X-ray). Radiation treatment. Oxygen rich environments such as hyperbaric chambers. Figure. Figure. Figure. Figure. Figure. Figure. Figure. Figure. Figure. Figure. Figure. Figure. Figure. Figure. Figure. Figure. Figure. Figure. Figure. Figure. Figure. Figure. Figure. Figure. Figure. Figure. Figure. Figure. Figure. Figure. Figure. Figure. Figure. Figure. Figure. Figure. Figure. Figure. Figure.

LACTATION SECTION.

8.2 Lactation. Risk SummaryThere are no data on the presence of pegfilgrastim in human milk, the effects on the breastfed child, or the effects on milk production. Other filgrastim products are secreted poorly into breast milk, and filgrastim products are not absorbed orally by neonates. The developmental and health benefits of breastfeeding should be considered along with the mothers clinical need for Neulasta and any potential adverse effects on the breastfed child from Neulasta or from the underlying maternal condition.

MECHANISM OF ACTION SECTION.

12.1 Mechanism of Action. Pegfilgrastim is colony-stimulating factor that acts on hematopoietic cells by binding to specific cell surface receptors, thereby stimulating proliferation, differentiation, commitment, and end cell functional activation.

NONCLINICAL TOXICOLOGY SECTION.

13 NONCLINICAL TOXICOLOGY. 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility. No carcinogenicity or mutagenesis studies have been performed with pegfilgrastim.Pegfilgrastim did not affect reproductive performance or fertility in male or female rats at cumulative weekly doses approximately to times higher than the recommended human dose (based on body surface area).

OVERDOSAGE SECTION.

10 OVERDOSAGE. Overdosage of Neulasta may result in leukocytosis and bone pain. Events of edema, dyspnea, and pleural effusion have been reported in single patient who administered Neulasta on consecutive days in error. In the event of overdose, the patient should be monitored for adverse reactions [see Adverse Reactions (6)].

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL.

PRINCIPAL DISPLAY PANEL Kit Carton. - Single Dose Neulasta Prefilled Syringe1 Sterile On-body Injector for NeulastaNDC 55513-192-01AMGEN(R) Neulasta(R) (pegfilgrastim) injection Onpro(R) kitPegylated Recombinant Methionyl Human Granulocyte Colony-Stimulating Factor (PEG-r-metHuG-CSF) derived from E. Coli6 mg/0.6 mL6 mg/0.6 mL Prefilled syringe contains 0.64 mL to deliver6 mg/0.6 mL when used with on-body injectorFor Subcutaneous Use OnlyCarton Contents (intended to be dispensed as unit):1 sterile On-body Injector for Neulasta Neulasta prefilled syringe labeled for use with on-body injector only patient instructions for use healthcare provider instructions for use, package insert This Product Contains Dry Natural RubberStore at to 8C (36 to 46F).Do Not Freeze or Shake. Keep in Carton to Protect from Light.See package insert for full prescribing information and Instructions for UseRx Only. sterile On-body Injector for Neulasta 1 Neulasta prefilled syringe labeled for use with on-body injector only 1 patient instructions for use 1 healthcare provider instructions for use, package insert PRINCIPAL DISPLAY PANEL Kit Carton.

PEDIATRIC USE SECTION.

8.4 Pediatric Use. The safety and effectiveness of Neulasta have been established in pediatric patients. No overall differences in safety were identified between adult and pediatric patients based on postmarketing surveillance and review of the scientific literature.Use of Neulasta in pediatric patients for chemotherapy-induced neutropenia is based on adequate and well-controlled studies in adults with additional pharmacokinetic and safety data in pediatric patients with sarcoma [see Clinical Pharmacology (12.3) and Clinical Studies (14.1)].The use of Neulasta to increase survival in pediatric patients acutely exposed to myelosuppressive doses of radiation is based on efficacy studies conducted in animals and clinical data supporting the use of Neulasta in patients with cancer receiving myelosuppressive chemotherapy. Efficacy studies of Neulasta could not be conducted in humans with acute radiation syndrome for ethical and feasibility reasons. Results from population modeling and simulation indicate that two doses of Neulasta (Table 1), administered one week apart provide pediatric patients with exposures comparable to that in adults receiving two mg doses one week apart [see Dosage and Administration (2.3), Clinical Pharmacology (12.3) and Clinical Studies (14.2)].

PHARMACODYNAMICS SECTION.

12.2 Pharmacodynamics. Animal data and clinical data in humans suggest correlation between pegfilgrastim exposure and the duration of severe neutropenia as predictor of efficacy. Selection of the dosing regimen of Neulasta is based on reducing the duration of severe neutropenia.

PHARMACOKINETICS SECTION.

12.3 Pharmacokinetics. The pharmacokinetics of pegfilgrastim was studied in 379 patients with cancer. The pharmacokinetics of pegfilgrastim was nonlinear, and clearance decreased with increases in dose. Neutrophil receptor binding is an important component of the clearance of pegfilgrastim, and serum clearance is directly related to the number of neutrophils. In addition to numbers of neutrophils, body weight appeared to be factor. Patients with higher body weights experienced higher systemic exposure to pegfilgrastim after receiving dose normalized for body weight. large variability in the pharmacokinetics of pegfilgrastim was observed. The half-life of Neulasta ranged from 15 to 80 hours after subcutaneous injection. In healthy volunteers, the pharmacokinetics of pegfilgrastim were comparable when delivered subcutaneously via manual prefilled syringe versus via the on-body injector (OBI) for Neulasta.. Specific PopulationsNo gender-related differences were observed in the pharmacokinetics of pegfilgrastim, and no differences were observed in the pharmacokinetics of geriatric patients (>= 65 years of age) compared with younger patients (< 65 years of age) [see Use in Specific Populations (8.5)]. Renal ImpairmentIn study of 30 subjects with varying degrees of renal dysfunction, including end stage renal disease, renal dysfunction had no effect on the pharmacokinetics of pegfilgrastim.. Pediatric Patients with Cancer Receiving Myelosuppressive ChemotherapyThe pharmacokinetics and safety of pegfilgrastim were studied in 37 pediatric patients with sarcoma in Study [see Clinical Studies (14.1)]. The mean (+- standard deviation [SD]) systemic exposure (AUC0-inf) of Neulasta after subcutaneous administration at 100 mcg/kg was 47.9 (+- 22.5) mcghr/mL in the youngest age group (0 to years, = 11), 22.0 (+- 13.1) mcghr/mL in the to 11 years age group (n 10), and 29.3 (+- 23.2) mcghr/mL in the 12 to 21 years age group (n 13). The terminal elimination half-lives of the corresponding age groups were 30.1 (+- 38.2) hours, 20.2 (+- 11.3) hours, and 21.2 (+- 16.0) hours, respectively. Patients Acutely Exposed to Myelosuppressive Doses of RadiationThe pharmacokinetics of pegfilgrastim is not available in patients acutely exposed to myelosuppressive doses of radiation. Based on limited pharmacokinetic data in irradiated non-human primates, the area under the concentration-time curve (AUC), reflecting the exposure to pegfilgrastim in non-human primates following 300 mcg/kg dose of Neulasta, appears to be greater than in humans receiving 6 mg dose. Results from population modeling and simulation indicate that two mg doses of Neulasta administered one week apart in adults result in clinically relevant effects on duration of grade and neutropenia. In addition, weight based dosing in pediatric patients weighing less than 45 kg [see Dosage and Administration, Section 2.3, Table 1] provides exposures comparable to those in adults receiving two mg doses one week apart.

POSTMARKETING EXPERIENCE SECTION.

6.3 Postmarketing Experience. The following adverse reactions have been identified during post approval use of Neulasta. Because these reactions are reported voluntarily from population of uncertain size, it is not always possible to reliably estimate their frequency or establish causal relationship to drug exposure.Splenic rupture and splenomegaly (enlarged spleen) [see Warnings and Precautions (5.1)] Acute respiratory distress syndrome (ARDS) [see Warnings and Precautions (5.2)] Allergic reactions/hypersensitivity, including anaphylaxis, skin rash, urticaria, generalized erythema, and flushing [see Warnings and Precautions (5.3)] Sickle cell crisis [see Warnings and Precautions (5.5)] Glomerulonephritis [see Warnings and Precautions (5.6)] Leukocytosis [see Warnings and Precautions (5.7)] Thrombocytopenia [see Warnings and Precautions (5.8)] Capillary Leak Syndrome [see Warnings and Precautions (5.9)] Injection site reactionsSweets syndrome (acute febrile neutrophilic dermatosis), cutaneous vasculitisApplication site reactions (including events such as application site hemorrhage, application site pain, application site discomfort, application site bruise, and application site erythema) have been reported with the use of the on-body injector for Neulasta.Contact dermatitis and local skin reactions such as rash, pruritus, and urticaria have been reported with the use of the on-body injector for Neulasta, possibly indicating hypersensitivity reaction to the adhesive.Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients with breast and lung cancer receiving chemotherapy and/or radiotherapy [see Warnings and Precautions (5.11)] Aortitis [see Warnings and Precautions (5.13)] Alveolar hemorrhage. Splenic rupture and splenomegaly (enlarged spleen) [see Warnings and Precautions (5.1)] Acute respiratory distress syndrome (ARDS) [see Warnings and Precautions (5.2)] Allergic reactions/hypersensitivity, including anaphylaxis, skin rash, urticaria, generalized erythema, and flushing [see Warnings and Precautions (5.3)] Sickle cell crisis [see Warnings and Precautions (5.5)] Glomerulonephritis [see Warnings and Precautions (5.6)] Leukocytosis [see Warnings and Precautions (5.7)] Thrombocytopenia [see Warnings and Precautions (5.8)] Capillary Leak Syndrome [see Warnings and Precautions (5.9)] Injection site reactions. Sweets syndrome (acute febrile neutrophilic dermatosis), cutaneous vasculitis. Application site reactions (including events such as application site hemorrhage, application site pain, application site discomfort, application site bruise, and application site erythema) have been reported with the use of the on-body injector for Neulasta.. Contact dermatitis and local skin reactions such as rash, pruritus, and urticaria have been reported with the use of the on-body injector for Neulasta, possibly indicating hypersensitivity reaction to the adhesive.. Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients with breast and lung cancer receiving chemotherapy and/or radiotherapy [see Warnings and Precautions (5.11)] Aortitis [see Warnings and Precautions (5.13)] Alveolar hemorrhage.

PREGNANCY SECTION.

8.1 Pregnancy. Risk SummaryAlthough available data with Neulasta use in pregnant women are insufficient to establish whether there is drug associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes, there are available data from published studies in pregnant women exposed to filgrastim products. These studies have not established an association of filgrastim product use during pregnancy with major birth defects, miscarriage, or adverse maternal or fetal outcomes.In animal studies, no evidence of reproductive/developmental toxicity occurred in the offspring of pregnant rats that received cumulative doses of pegfilgrastim approximately 10 times the recommended human dose (based on body surface area). In pregnant rabbits, increased embryolethality and spontaneous abortions occurred at times the maximum recommended human dose simultaneously with signs of maternal toxicity (see Data). The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risks of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.. Data. Animal DataPregnant rabbits were dosed with pegfilgrastim subcutaneously every other day during the period of organogenesis. At cumulative doses ranging from the approximate human dose to approximately times the recommended human dose (based on body surface area), the treated rabbits exhibited decreased maternal food consumption, maternal weight loss, as well as reduced fetal body weights and delayed ossification of the fetal skull; however, no structural anomalies were observed in the offspring from either study. Increased incidences of post-implantation losses and spontaneous abortions (more than half the pregnancies) were observed at cumulative doses approximately times the recommended human dose, which were not seen when pregnant rabbits were exposed to the recommended human dose.Three studies were conducted in pregnant rats dosed with pegfilgrastim at cumulative doses up to approximately 10 times the recommended human dose at the following stages of gestation: during the period of organogenesis, from mating through the first half of pregnancy, and from the first trimester through delivery and lactation. No evidence of fetal loss or structural malformations was observed in any study. Cumulative doses equivalent to approximately and 10 times the recommended human dose resulted in transient evidence of wavy ribs in fetuses of treated mothers (detected at the end of gestation but no longer present in pups evaluated at the end of lactation).

RECENT MAJOR CHANGES SECTION.

Warnings and Precautions, Thrombocytopenia (5.8)01/2021Warnings and Precautions, Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) (5.11) 01/2021.

SPL PATIENT PACKAGE INSERT SECTION.

Patient Information Neulasta(R) (nu-las-tah) (pegfilgrastim) injection Single-Dose Prefilled SyringeThis Patient Information has been approved by the U.S. Food and Drug Administration. Revised: 01/2021What is NeulastaNeulasta is man-made form of granulocyte colony-stimulating factor (G-CSF). G-CSF is substance produced by the body. It stimulates the growth of neutrophils, type of white blood cell important in the bodys fight against infection.Acute Radiation Syndrome: The effectiveness of Neulasta for this use was only studied in animals, because it could not be studied in people. Do not take Neulasta if you have had serious allergic reaction to pegfilgrastim or filgrastim.Before you receive Neulasta, tell your healthcare provider about all of your medical conditions, including if you:have sickle cell disorder.have kidney problems.are allergic to latex. The needle cap on the prefilled syringe contains dry natural rubber (derived from latex). You should not give Neulasta using the prefilled syringe if you have latex allergies.are pregnant or plan to become pregnant. It is not known if Neulasta will harm your unborn baby.are breastfeeding or plan to breastfeed. It is not known if Neulasta passes into your breast milk.Tell your healthcare provider about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.How will receive NeulastaNeulasta is given as an injection under your skin (subcutaneous injection) by healthcare provider. If your healthcare provider decides that the subcutaneous injections can be given at home by you or your caregiver, follow the detailed Instructions for Use that comes with your Neulasta for information on how to prepare and inject dose of Neulasta.You and your caregiver will be shown how to prepare and inject Neulasta before you use it.You should not inject dose of Neulasta to children weighing less than 45 kg from Neulasta prefilled syringe. dose less than 0.6 mL (6 mg) cannot be accurately measured using the Neulasta prefilled syringe.If you are receiving Neulasta because you are also receiving chemotherapy, the last dose of Neulasta should be injected at least 14 days before and 24 hours after your dose of chemotherapy.If you miss dose of Neulasta, talk to your healthcare provider about when you should give your next dose.What are possible side effects of Neulasta Neulasta may cause serious side effects, including:Spleen rupture. Your spleen may become enlarged and can rupture. ruptured spleen can cause death. Call your healthcare provider right away if you have pain in the left upper stomach area or your left shoulder. serious lung problem called Acute Respiratory Distress Syndrome (ARDS). Call your healthcare provider or get emergency help right away if you have shortness of breath with or without fever, trouble breathing, or fast rate of breathing.Serious allergic reactions. Neulasta can cause serious allergic reactions. These reactions can cause rash over your whole body, shortness of breath, wheezing, dizziness, swelling around your mouth or eyes, fast heart rate, and sweating. If you have any of these symptoms, stop using Neulasta and call your healthcare provider or get emergency medical help right away.Sickle cell crises. You may have serious sickle cell crisis, which could lead to death, if you have sickle cell disorder and receive Neulasta. Call your healthcare provider right away if you have symptoms of sickle cell crisis such as pain or difficulty breathing.Kidney injury (glomerulonephritis). Neulasta can cause kidney injury. Call your healthcare provider right away if you develop any of the following symptoms: swelling of your face or ankles blood in your urine or dark colored urine you urinate less than usual Increased white blood cell count (leukocytosis). Your healthcare provider will check your blood during treatment with Neulasta.Decreased platelet count (thrombocytopenia). Your healthcare provider will check your blood during treatment with Neulasta. Tell your healthcare provider if you have unusual bleeding or bruising during treatment with Neulasta. This could be sign of decreased platelet counts, which may reduce the ability of your blood to clot. Capillary Leak Syndrome. Neulasta can cause fluid to leak from blood vessels into your bodys tissues. This condition is called Capillary Leak Syndrome (CLS). CLS can quickly cause you to have symptoms that may become life-threatening. Get emergency medical help right away if you develop any of the following symptoms:swelling or puffiness and are urinating less than usualtrouble breathing swelling of your stomach area (abdomen) and feeling of fullness dizziness or feeling fainta general feeling of tiredness Myelodysplastic syndrome and acute myeloid leukemia. If you have breast cancer or lung cancer, when Neulasta is used with chemotherapy and radiation therapy, or with radiation therapy alone, you may have an increased risk of developing precancerous blood condition called myelodysplastic syndrome (MDS) or blood cancer called acute myeloid leukemia (AML). Symptoms of MDS and AML may include tiredness, fever, and easy bruising or bleeding. Call your healthcare provider if you develop these symptoms during treatment with Neulasta. Inflammation of the aorta (aortitis). Inflammation of the aorta (the large blood vessel which transports blood from the heart to the body) has been reported in patients who received Neulasta. Symptoms may include fever, abdominal pain, feeling tired, and back pain. Call your healthcare provider if you experience these symptoms. The most common side effects of Neulasta are pain in the bones, arms, and legs. These are not all the possible side effects of Neulasta. Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.How should store NeulastaStore Neulasta in the refrigerator between 36F to 46F (2C to 8C). Do not freeze.Keep the prefilled syringe in the original carton to protect from light or physical damage. Do not shake the prefilled syringe.Take Neulasta out of the refrigerator 30 minutes before use and allow it to reach room temperature before preparing an injection. Throw away (dispose of) any Neulasta that has been left at room temperature, 68F to 77F (20C to 25C), for more than 48 hours. Keep the Neulasta prefilled syringe out of the reach of children.General information about the safe and effective use of Neulasta.Medicines are sometimes prescribed for purposes other than those listed in Patient Information leaflet. Do not use Neulasta for condition for which it was not prescribed. Do not give Neulasta to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about Neulasta that is written for health professionals.What are the ingredients in NeulastaActive ingredient: pegfilgrastim Inactive ingredients: acetate, polysorbate 20, sodium and sorbitol in water for injection. Manufactured by: Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799 U.S. License No. 1080Patent: http://pat.amgen.com/onpro/ (C)2002- 2021 Amgen Inc. All rights reserved. For more information go to www.neulasta.com, or call 1-800-77-AMGEN (1-800-772-6436). 1xxxxx v16. have sickle cell disorder.. have kidney problems.. are allergic to latex. The needle cap on the prefilled syringe contains dry natural rubber (derived from latex). You should not give Neulasta using the prefilled syringe if you have latex allergies.. are pregnant or plan to become pregnant. It is not known if Neulasta will harm your unborn baby.. are breastfeeding or plan to breastfeed. It is not known if Neulasta passes into your breast milk.. Neulasta is given as an injection under your skin (subcutaneous injection) by healthcare provider. If your healthcare provider decides that the subcutaneous injections can be given at home by you or your caregiver, follow the detailed Instructions for Use that comes with your Neulasta for information on how to prepare and inject dose of Neulasta.. You and your caregiver will be shown how to prepare and inject Neulasta before you use it.. You should not inject dose of Neulasta to children weighing less than 45 kg from Neulasta prefilled syringe. dose less than 0.6 mL (6 mg) cannot be accurately measured using the Neulasta prefilled syringe.. If you are receiving Neulasta because you are also receiving chemotherapy, the last dose of Neulasta should be injected at least 14 days before and 24 hours after your dose of chemotherapy.. If you miss dose of Neulasta, talk to your healthcare provider about when you should give your next dose.. Spleen rupture. Your spleen may become enlarged and can rupture. ruptured spleen can cause death. Call your healthcare provider right away if you have pain in the left upper stomach area or your left shoulder. A serious lung problem called Acute Respiratory Distress Syndrome (ARDS). Call your healthcare provider or get emergency help right away if you have shortness of breath with or without fever, trouble breathing, or fast rate of breathing.. Serious allergic reactions. Neulasta can cause serious allergic reactions. These reactions can cause rash over your whole body, shortness of breath, wheezing, dizziness, swelling around your mouth or eyes, fast heart rate, and sweating. If you have any of these symptoms, stop using Neulasta and call your healthcare provider or get emergency medical help right away.. Sickle cell crises. You may have serious sickle cell crisis, which could lead to death, if you have sickle cell disorder and receive Neulasta. Call your healthcare provider right away if you have symptoms of sickle cell crisis such as pain or difficulty breathing.. Kidney injury (glomerulonephritis). Neulasta can cause kidney injury. Call your healthcare provider right away if you develop any of the following symptoms: swelling of your face or ankles blood in your urine or dark colored urine you urinate less than usual swelling of your face or ankles blood in your urine or dark colored urine you urinate less than usual. Increased white blood cell count (leukocytosis). Your healthcare provider will check your blood during treatment with Neulasta.. Decreased platelet count (thrombocytopenia). Your healthcare provider will check your blood during treatment with Neulasta. Tell your healthcare provider if you have unusual bleeding or bruising during treatment with Neulasta. This could be sign of decreased platelet counts, which may reduce the ability of your blood to clot. Capillary Leak Syndrome. Neulasta can cause fluid to leak from blood vessels into your bodys tissues. This condition is called Capillary Leak Syndrome (CLS). CLS can quickly cause you to have symptoms that may become life-threatening. Get emergency medical help right away if you develop any of the following symptoms:swelling or puffiness and are urinating less than usualtrouble breathing swelling of your stomach area (abdomen) and feeling of fullness dizziness or feeling fainta general feeling of tiredness swelling or puffiness and are urinating less than usual. trouble breathing swelling of your stomach area (abdomen) and feeling of fullness dizziness or feeling faint. general feeling of tiredness. Myelodysplastic syndrome and acute myeloid leukemia. If you have breast cancer or lung cancer, when Neulasta is used with chemotherapy and radiation therapy, or with radiation therapy alone, you may have an increased risk of developing precancerous blood condition called myelodysplastic syndrome (MDS) or blood cancer called acute myeloid leukemia (AML). Symptoms of MDS and AML may include tiredness, fever, and easy bruising or bleeding. Call your healthcare provider if you develop these symptoms during treatment with Neulasta. Inflammation of the aorta (aortitis). Inflammation of the aorta (the large blood vessel which transports blood from the heart to the body) has been reported in patients who received Neulasta. Symptoms may include fever, abdominal pain, feeling tired, and back pain. Call your healthcare provider if you experience these symptoms. Store Neulasta in the refrigerator between 36F to 46F (2C to 8C). Do not freeze.. Keep the prefilled syringe in the original carton to protect from light or physical damage. Do not shake the prefilled syringe.. Take Neulasta out of the refrigerator 30 minutes before use and allow it to reach room temperature before preparing an injection. Throw away (dispose of) any Neulasta that has been left at room temperature, 68F to 77F (20C to 25C), for more than 48 hours.

SPL UNCLASSIFIED SECTION.

1.1 Patients with Cancer Receiving Myelosuppressive Chemotherapy. Neulasta is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia [see Clinical Studies (14.1)].. Limitations of UseNeulasta is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.

STORAGE AND HANDLING SECTION.

Store refrigerated between 36F to 46F (2C to 8C) in the carton to protect from light. Do not shake. Discard syringes stored at room temperature for more than 48 hours. Avoid freezing; if frozen, thaw in the refrigerator before administration. Discard syringe if frozen more than once.

USE IN SPECIFIC POPULATIONS SECTION.

8 USE IN SPECIFIC POPULATIONS. 8.1 Pregnancy. Risk SummaryAlthough available data with Neulasta use in pregnant women are insufficient to establish whether there is drug associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes, there are available data from published studies in pregnant women exposed to filgrastim products. These studies have not established an association of filgrastim product use during pregnancy with major birth defects, miscarriage, or adverse maternal or fetal outcomes.In animal studies, no evidence of reproductive/developmental toxicity occurred in the offspring of pregnant rats that received cumulative doses of pegfilgrastim approximately 10 times the recommended human dose (based on body surface area). In pregnant rabbits, increased embryolethality and spontaneous abortions occurred at times the maximum recommended human dose simultaneously with signs of maternal toxicity (see Data). The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risks of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.. Data. Animal DataPregnant rabbits were dosed with pegfilgrastim subcutaneously every other day during the period of organogenesis. At cumulative doses ranging from the approximate human dose to approximately times the recommended human dose (based on body surface area), the treated rabbits exhibited decreased maternal food consumption, maternal weight loss, as well as reduced fetal body weights and delayed ossification of the fetal skull; however, no structural anomalies were observed in the offspring from either study. Increased incidences of post-implantation losses and spontaneous abortions (more than half the pregnancies) were observed at cumulative doses approximately times the recommended human dose, which were not seen when pregnant rabbits were exposed to the recommended human dose.Three studies were conducted in pregnant rats dosed with pegfilgrastim at cumulative doses up to approximately 10 times the recommended human dose at the following stages of gestation: during the period of organogenesis, from mating through the first half of pregnancy, and from the first trimester through delivery and lactation. No evidence of fetal loss or structural malformations was observed in any study. Cumulative doses equivalent to approximately and 10 times the recommended human dose resulted in transient evidence of wavy ribs in fetuses of treated mothers (detected at the end of gestation but no longer present in pups evaluated at the end of lactation).. 8.2 Lactation. Risk SummaryThere are no data on the presence of pegfilgrastim in human milk, the effects on the breastfed child, or the effects on milk production. Other filgrastim products are secreted poorly into breast milk, and filgrastim products are not absorbed orally by neonates. The developmental and health benefits of breastfeeding should be considered along with the mothers clinical need for Neulasta and any potential adverse effects on the breastfed child from Neulasta or from the underlying maternal condition.. 8.4 Pediatric Use. The safety and effectiveness of Neulasta have been established in pediatric patients. No overall differences in safety were identified between adult and pediatric patients based on postmarketing surveillance and review of the scientific literature.Use of Neulasta in pediatric patients for chemotherapy-induced neutropenia is based on adequate and well-controlled studies in adults with additional pharmacokinetic and safety data in pediatric patients with sarcoma [see Clinical Pharmacology (12.3) and Clinical Studies (14.1)].The use of Neulasta to increase survival in pediatric patients acutely exposed to myelosuppressive doses of radiation is based on efficacy studies conducted in animals and clinical data supporting the use of Neulasta in patients with cancer receiving myelosuppressive chemotherapy. Efficacy studies of Neulasta could not be conducted in humans with acute radiation syndrome for ethical and feasibility reasons. Results from population modeling and simulation indicate that two doses of Neulasta (Table 1), administered one week apart provide pediatric patients with exposures comparable to that in adults receiving two mg doses one week apart [see Dosage and Administration (2.3), Clinical Pharmacology (12.3) and Clinical Studies (14.2)]. 8.5 Geriatric Use. Of the 932 patients with cancer who received Neulasta in clinical studies, 139 (15%) were aged 65 and over, and 18 (2%) were aged 75 and over. No overall differences in safety or effectiveness were observed between patients aged 65 and older and younger patients.

WARNINGS AND PRECAUTIONS SECTION.

5 WARNINGS AND PRECAUTIONS. Fatal splenic rupture: Evaluate patients who report left upper abdominal or shoulder pain for an enlarged spleen or splenic rupture. (5.1) Acute respiratory distress syndrome (ARDS): Evaluate patients who develop fever, lung infiltrates, or respiratory distress. Discontinue Neulasta in patients with ARDS. (5.2) Serious allergic reactions, including anaphylaxis: Permanently discontinue Neulasta in patients with serious allergic reactions. (5.3) The on-body injector for Neulasta uses acrylic adhesive. For patients who have reactions to acrylic adhesives, use of this product may result in significant reaction. (5.4) Fatal sickle cell crises: Discontinue Neulasta if sickle cell crisis occurs. (5.5) Glomerulonephritis: Evaluate and consider dose-reduction or interruption of Neulasta if causality is likely. (5.6) Thrombocytopenia: Monitor platelet counts. (5.8) Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML): Monitor patients with breast and lung cancer using Neulasta in conjunction with chemotherapy and/or radiotherapy for signs and symptoms of MDS/AML. (5.11) Potential device failures: Instruct patients to notify their healthcare provider if they suspect the on-body injector may not have performed as intended. (5.12). Fatal splenic rupture: Evaluate patients who report left upper abdominal or shoulder pain for an enlarged spleen or splenic rupture. (5.1). Acute respiratory distress syndrome (ARDS): Evaluate patients who develop fever, lung infiltrates, or respiratory distress. Discontinue Neulasta in patients with ARDS. (5.2). Serious allergic reactions, including anaphylaxis: Permanently discontinue Neulasta in patients with serious allergic reactions. (5.3). The on-body injector for Neulasta uses acrylic adhesive. For patients who have reactions to acrylic adhesives, use of this product may result in significant reaction. (5.4). Fatal sickle cell crises: Discontinue Neulasta if sickle cell crisis occurs. (5.5). Glomerulonephritis: Evaluate and consider dose-reduction or interruption of Neulasta if causality is likely. (5.6). Thrombocytopenia: Monitor platelet counts. (5.8). Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML): Monitor patients with breast and lung cancer using Neulasta in conjunction with chemotherapy and/or radiotherapy for signs and symptoms of MDS/AML. (5.11). Potential device failures: Instruct patients to notify their healthcare provider if they suspect the on-body injector may not have performed as intended. (5.12). 5.1 Splenic Rupture. Splenic rupture, including fatal cases, can occur following the administration of Neulasta. Evaluate for an enlarged spleen or splenic rupture in patients who report left upper abdominal or shoulder pain after receiving Neulasta.. 5.2 Acute Respiratory Distress Syndrome. Acute respiratory distress syndrome (ARDS) can occur in patients receiving Neulasta. Evaluate patients who develop fever and lung infiltrates or respiratory distress after receiving Neulasta, for ARDS. Discontinue Neulasta in patients with ARDS.. 5.3 Serious Allergic Reactions. Serious allergic reactions, including anaphylaxis, can occur in patients receiving Neulasta. The majority of reported events occurred upon initial exposure. Allergic reactions, including anaphylaxis, can recur within days after the discontinuation of initial anti-allergic treatment. Permanently discontinue Neulasta in patients with serious allergic reactions. Do not administer Neulasta to patients with history of serious allergic reactions to pegfilgrastim or filgrastim.. 5.4 Allergies to Acrylics. The on-body injector (OBI) for Neulasta uses acrylic adhesive. For patients who have reactions to acrylic adhesives, use of this product may result in significant reaction.. 5.5 Use in Patients with Sickle Cell Disorders. Severe and sometimes fatal sickle cell crises can occur in patients with sickle cell disorders receiving pegfilgrastim products. Discontinue Neulasta if sickle cell crisis occurs. 5.6 Glomerulonephritis. Glomerulonephritis has occurred in patients receiving Neulasta. The diagnoses were based upon azotemia, hematuria (microscopic and macroscopic), proteinuria, and renal biopsy. Generally, events of glomerulonephritis resolved after dose-reduction or discontinuation of Neulasta. If glomerulonephritis is suspected, evaluate for cause. If causality is likely, consider dose-reduction or interruption of Neulasta.. 5.7 Leukocytosis. White blood cell (WBC) counts of 100 109/L or greater have been observed in patients receiving pegfilgrastim. Monitoring of complete blood count (CBC) during pegfilgrastim therapy is recommended. 5.8 Thrombocytopenia. Thrombocytopenia has been reported in patients receiving pegfilgrastim. Monitor platelet counts.. 5.9 Capillary Leak Syndrome. Capillary leak syndrome has been reported after G-CSF administration, including Neulasta, and is characterized by hypotension, hypoalbuminemia, edema and hemoconcentration. Episodes vary in frequency, severity and may be life-threatening if treatment is delayed. Patients who develop symptoms of capillary leak syndrome should be closely monitored and receive standard symptomatic treatment, which may include need for intensive care.. 5.10 Potential for Tumor Growth Stimulatory Effects on Malignant Cells. The granulocyte colony-stimulating factor (G-CSF) receptor through which pegfilgrastim and filgrastim act has been found on tumor cell lines. The possibility that pegfilgrastim acts as growth factor for any tumor type, including myeloid malignancies and myelodysplasia, diseases for which pegfilgrastim is not approved, cannot be excluded.. 5.11Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) in Patients with Breast and Lung Cancer MDS and AML have been associated with the use of Neulasta in conjunction with chemotherapy and/or radiotherapy in patients with breast and lung cancer. Monitor patients for signs and symptoms of MDS/AML in these settings. 5.12Potential Device Failures. Missed or partial doses have been reported in patients receiving Neulasta via the on-body injector (OBI) due to the device not performing as intended. In the event of missed or partial dose, patients may be at increased risk of events such as neutropenia, febrile neutropenia and/or infection than if the dose had been correctly delivered. Instruct patients using the OBI to notify their healthcare professional immediately in order to determine the need for replacement dose of Neulasta if they suspect that the device may not have performed as intended.. 5.13 Aortitis. Aortitis has been reported in patients receiving Neulasta. It may occur as early as the first week after start of therapy. Manifestations may include generalized signs and symptoms such as fever, abdominal pain, malaise, back pain, and increased inflammatory markers (e.g., c-reactive protein and white blood cell count). Consider aortitis in patients who develop these signs and symptoms without known etiology. Discontinue Neulasta if aortitis is suspected.. 5.14 Nuclear Imaging. Increased hematopoietic activity of the bone marrow in response to growth factor therapy has been associated with transient positive bone imaging changes. This should be considered when interpreting bone imaging results.